Show simple item record

dc.contributor.authorHarrold, Leslie R.
dc.contributor.authorPatterson, M. Kay
dc.contributor.authorAndrade, Susan E.
dc.contributor.authorDube, Timothy
dc.contributor.authorGo, Alan S.
dc.contributor.authorBuist, A. Sonia
dc.contributor.authorChan, K. Arnold
dc.contributor.authorWeller, Peter F.
dc.contributor.authorWechsler, Michael E.
dc.contributor.authorYood, Robert A.
dc.contributor.authorDavis, Kourtney J.
dc.contributor.authorPlatt, Richard
dc.contributor.authorWalker, Alexander M.
dc.date2022-08-11T08:09:21.000
dc.date.accessioned2022-08-23T16:27:43Z
dc.date.available2022-08-23T16:27:43Z
dc.date.issued2006-12-29
dc.date.submitted2010-04-30
dc.identifier.citationPharmacoepidemiol Drug Saf. 2007 Jun;16(6):620-6. <a href="http://dx.doi.org/10.1002/pds.1353">Link to article on publisher's site</a>
dc.identifier.issn1053-8569 (Linking)
dc.identifier.doi10.1002/pds.1353
dc.identifier.pmid17192840
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36850
dc.description.abstractPURPOSE: Case reports suggest that leukotriene modifier use may be associated with the onset of Churg-Strauss syndrome (CSS). Using pooled data from two nested case-control studies, we examined the association between asthma drug use and the development of CSS. METHODS: The study was performed in three US managed care organizations and a US national health plan with chart access and complete electronic pharmacy data, with a covered population of 13.9 million. There were 47 cases of possible or definite CSS and 4700 asthma drug user controls identified between January 1, 1995 and December 31, 2002. We examined exposure to asthma drugs in cases and controls, including leukotriene modifiers (6 cases and 202 controls), in the two to 6 months prior to the onset of adjudicated CSS. RESULTS: While the crude association between use of leukotriene modifiers and CSS was strong (odds ratio (OR) 4.00, 95% confidence interval (CI): 1.49-10.60), in a multivariable analysis controlling for use of oral corticosteroids, inhaled corticosteroids, and number of categories of asthma drugs dispensed, there was no significant association (OR 1.32, 95% CI: 0.44-3.96). Use of inhaled and oral corticosteroids, evaluated as markers of asthma severity, were associated with CSS (OR 3.07, 95% CI: 1.34-7.03 and OR 5.36, 95% CI: 2.51-11.45, respectively). CONCLUSIONS: No association was found between CSS and leukotriene modifiers after controlling for asthma drug use However, it is not possible to rule out modest associations with asthma treatments given CSS is so rare and so highly correlated with asthma severity, suggesting further investigation is warranted.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17192840&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/pds.1353
dc.subjectAdolescent
dc.subjectAdrenal Cortex Hormones
dc.subjectAdult
dc.subjectAged
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectCase-Control Studies
dc.subjectChurg-Strauss Syndrome
dc.subjectFemale
dc.subjectHumans
dc.subjectLeukotriene Antagonists
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectHealth Services Research
dc.subjectMedicine and Health Sciences
dc.titleAsthma drug use and the development of Churg-Strauss syndrome (CSS)
dc.typeJournal Article
dc.source.journaltitlePharmacoepidemiology and drug safety
dc.source.volume16
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/225
dc.identifier.contextkey1293959
html.description.abstract<p>PURPOSE: Case reports suggest that leukotriene modifier use may be associated with the onset of Churg-Strauss syndrome (CSS). Using pooled data from two nested case-control studies, we examined the association between asthma drug use and the development of CSS.</p> <p>METHODS: The study was performed in three US managed care organizations and a US national health plan with chart access and complete electronic pharmacy data, with a covered population of 13.9 million. There were 47 cases of possible or definite CSS and 4700 asthma drug user controls identified between January 1, 1995 and December 31, 2002. We examined exposure to asthma drugs in cases and controls, including leukotriene modifiers (6 cases and 202 controls), in the two to 6 months prior to the onset of adjudicated CSS.</p> <p>RESULTS: While the crude association between use of leukotriene modifiers and CSS was strong (odds ratio (OR) 4.00, 95% confidence interval (CI): 1.49-10.60), in a multivariable analysis controlling for use of oral corticosteroids, inhaled corticosteroids, and number of categories of asthma drugs dispensed, there was no significant association (OR 1.32, 95% CI: 0.44-3.96). Use of inhaled and oral corticosteroids, evaluated as markers of asthma severity, were associated with CSS (OR 3.07, 95% CI: 1.34-7.03 and OR 5.36, 95% CI: 2.51-11.45, respectively).</p> <p>CONCLUSIONS: No association was found between CSS and leukotriene modifiers after controlling for asthma drug use However, it is not possible to rule out modest associations with asthma treatments given CSS is so rare and so highly correlated with asthma severity, suggesting further investigation is warranted.</p>
dc.identifier.submissionpathmeyers_pp/225
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages620-6


This item appears in the following Collection(s)

Show simple item record